Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, Nishida N, Ogawa C, Tomonari T, Nakamura N, Kuroda H, Takebe A, Takeyama Y, Hidaka M, Eguchi S, Chan SL, Kurosaki M, Izumi N. Kudo M, et al. Among authors: chan sl. Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep. Liver Cancer. 2023. PMID: 37901197 Free PMC article.
Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma.
Chan SL, Wong LL, Chan KA, Chow C, Tong JH, Yip TC, Wong GL, Chong CC, Liu PH, Chu CM, Wong VW, To KF, Reeves HL, Chan AW. Chan SL, et al. Among authors: chan ka, chan aw. Liver Cancer. 2020 Apr;9(2):167-181. doi: 10.1159/000504252. Epub 2019 Nov 21. Liver Cancer. 2020. PMID: 32399431 Free PMC article.
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, Kudo M. Ryoo BY, et al. Among authors: chan sl. Cancer. 2021 Mar 15;127(6):865-874. doi: 10.1002/cncr.33317. Epub 2020 Nov 24. Cancer. 2021. PMID: 33231873 Free article. Clinical Trial.
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.
Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, Shim JH, Lim YS, Lee HC, Lee J, Tai D, Chan SL, Ryoo BY. Yoo C, et al. Among authors: chan sl. Liver Cancer. 2021 Apr;10(2):107-114. doi: 10.1159/000512781. Epub 2021 Mar 3. Liver Cancer. 2021. PMID: 33977087 Free PMC article.
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.
Vogel A, Merle P, Verslype C, Finn RS, Zhu AX, Cheng AL, Chan SL, Yau T, Ryoo BY, Knox J, Daniele B, Qin S, Wei Z, Miteva Y, Malhotra U, Siegel AB, Kudo M. Vogel A, et al. Among authors: chan sl. Ther Adv Med Oncol. 2021 Sep 30;13:17588359211039928. doi: 10.1177/17588359211039928. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34616489 Free PMC article.
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillén-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Delord JP. Chan SL, et al. J Exp Clin Cancer Res. 2022 Jun 2;41(1):189. doi: 10.1186/s13046-022-02383-5. J Exp Clin Cancer Res. 2022. PMID: 35655320 Free PMC article. Clinical Trial.
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan.
Yau T, Tai D, Chan SL, Huang YH, Choo SP, Hsu C, Cheung TT, Lin SM, Yong WP, Lee J, Leung T, Shum T, Yeung CSY, Tai AY, Law ALY, Cheng AL, Chen LT. Yau T, et al. Among authors: chan sl. Liver Cancer. 2022 Jun 17;11(5):426-439. doi: 10.1159/000525582. eCollection 2022 Sep. Liver Cancer. 2022. PMID: 36158587 Free PMC article. Review.
670 results